Blood Thinner Archives - Page 2 of 2

NIH Pushing Large-Scale, Organized COVID-19 Trials

"Operation Warp Speed" Initiative, Blood Clots, Blood Thinner, Clinical Trials, Coronavirus Disease 2019 (COVID-19), COVID-19 Vaccines, Cytokines, Hospitalized COVID-19 Patients, Immune System, Monoclonal Antibodies, National Institutes of Health, R&D, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

The National Institutes of Health (NIH) announced plans to launch a “flurry” of large-scale clinical trials for treating Covid-19.

July 23, 2020/by BioSpace

FDA approves first generic of blood thinner Eliquis

Approvals, Blood Thinner, FDA, FDA/Regulatory

The U.S. Food and Drug Administration approved the first generic version of Bristol-Myers Squibb Co. and Pfizer Inc.’s blood thinner Eliquis.

December 23, 2019/by Reuters Health

Bristol-Myers posts better-than-expected results, Opdivo growth slows

Advanced lung cancer, Analysts, Biotechnology, Blockbusters, Blood Thinner, Cancer, Data, Immunotherapies, Investors, Leukemia, Rheumatoid Arthritis, Wall Street Estimates

U.S. drugmaker Bristol-Myers Squibb Co. reported higher-than-expected third-quarter 2019 profit, helped by strong sales of the blood thinner Eliquis, even as growth of the company’s blockbuster cancer treatment Opdivo slowed.

October 31, 2019/by Reuters Health

Bristol-Myers posts strong second quarter 2019 earnings as Eliquis, Orencia surprise

Biotechnology, Blockbusters, Blood Thinner, Rheumatoid Arthritis

Bristol-Myers Squibb Co., which is set to buy biotechnology company Celgene Corp. for $74 billion, posted better-than-expected second-quarter 2019 earnings on strong sales from the blood thinner Eliquis and the rheumatoid arthritis treatment Orencia.

July 25, 2019/by Reuters Health

FDA approves first anticoagulant for pediatric patients to treat potentially life-threatening blood clots

Anticoagulants, Approvals, Blood Thinner, Boxed Warning, Congenital Heart Disease, FDA, FDA/Regulatory, New Indications, Priority Review Status, Symptomatic Venous Thromboembolism (VTE)

The U.S. FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism in pediatric patients 1 month of age and older.

May 16, 2019/by PR Newswire

Bayer, J&J settle U.S. Xarelto litigation for $775 million

Blockbusters, Blood Clots, Blood Thinner, Business, Doctors, Lawsuits, Liability Insurance, Litigation, Sales, Therapeutics

Bayer AG and Johnson & Johnson agreed to settle more than 25,000 U.S. lawsuits over the companies’ blockbuster blood thinner Xarelto for a total of $775 million, court documents showed.

March 25, 2019/by Reuters Health

Med Ad News’ first edition of the Pharma Leaders of Innovation special feature showcases two CEOs focusing outside the big pharma box and an agency tech leader.

August 17, 2016/by Christiane Truelove